The body usually maintains carnitine levels through a combination of internal production and diet
Studies have shown, however, that taking L-carnitine both orally as well as intravenously can both prevent and treat low levels of L-carnitine and associated symptoms such as anemia and inflammation
Based on prior trial data, how should we benchmark current obesity drugswhere is the bar set
Cross-talk between antigen presenting cells and T cells impacts intestinal homeostasis, bacterial infections, and tumorigenesis
While some trials show no major changes in BMD, others suggest slight improvements in bone turnover markers: Trials of liraglutide and exenatide generally show stable BMD over 612 months Certain populations such as postmenopausal women or individuals with rapid weight loss may show changes in bone markers like osteocalcin and P1NP However, most of these studies are small, short-term, or not powered for skeletal endpoints
A single treatment can offer a temporary boost, but sustained benefits require repeated dosing that keeps plasma concentrations elevated over time